A probable relationship between an endogenous digitalis-like substance and concentric cardiac hypertrophy in primary aldosteronism

Internal Medicine

Volumn 38, Issue 8, 1999, Pages 655-659

  Shimada, Toshio ^a   Nagasaka, Yukihiro ^a   Ishibashi, Yutaka ^a   Tsukihashi, Hironori ^a   Murakami, Yo ^a   Sano, Kazuya ^a   Tanabe, Kazuaki ^a   Hiroyuki, Yoshitomi ^a   Murakami, Rinji ^a   Morioka, Shigefumi ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

Adenoma of the adrenal gland; Secondary hypertension

Indexed keywords

CARDENOLIDE; DIGOXIN; DIGOXIN LIKE FACTORS; DIGOXIN-LIKE FACTORS; SAPONIN;

ADRENAL TUMOR; ADULT; ARTICLE; BLOOD; CASE REPORT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION;

ADRENAL GLAND NEOPLASMS; ADULT; CARDENOLIDES; DIGOXIN; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; SAPONINS;

EID: 0033174534     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.655     Document Type: Article

References (19)

1. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45: 3-17, 1955.
2. Onoyama K, Bravo EL, Tarazi RC. Sodium extracellular fluid volume, and cardiac output changes in the genesis of mineral corticoid hypertension in the intact dog. Hypertension 1: 331-336, 1979.
3. Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of iron transport. Hypertension 19: 221-227, 1992.
4. Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineral corticoids: role of ANF and intrarenal hormone systems. Kidney Int 35: 767-777, 1989.
5. Ferriss JB, Beevers DG, Brown JJ, et al. Clinical, biochemical and pathological features of low-renin ("primary") hyperaldosteronism. Am Heart J 95: 375-388, 1978.
6. Leddingham JG, Laragh JH, Sommers SC. Secondary aldosteronism and reduced plasma renin in hypertensive disease. Trans Assoc Am Physicians 80: 168-182, 1967.
7. Alterman SL, Dominguez C, Lopez-Gomez A, Liebe A. Primary adrenocortical carcinoma causing aldosteronism. Cancer 24: 602-609, 1969.
8. Tarazi RC, Ibrahim MM, Bravo EL, Dustan HP. Hemodynamic characteristics of primary aldosteronism. N Engl J Med 289: 1330-1335, 1973.
9. Davies DL, Beevers DG, Brown JJ, et al. Aldosterone and its stimuli in normal and hypertensive man: Are essential hypertension and primary hyperaldosteronism without tumor the same condition? J Endocrin 81: 70-91, 1979.
10. Shionoiri H, Hirawa N, Ueda S, et al. Renin gene expression in the adrenal and kidney of patients with primary aldosteronism. J Clin Endocrinol Metab 74: 103-107, 1992.
11. Cocci F, Clerico A, Paci A, et al. Radioreceptor assay for the measurement of endogenous digitalis-like factors using membrane particulate fraction of human placenta and 1251-digoxin: comparison with RIA method. J Nucl Med Allied Sci 34: 24-28, 1990.
12. Haddy FJ, Pamnani MB. Pharmacologic agents for the in vivo detection of vascular sodium transport defects in hypertension. Life Sci 41: 2685-2696, 1987.
13. Graves SW, Eder JP, Schryber SM, et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologus bone marrow transplantation. Clin Sci 77: 501-507, 1989.
14. Bagrov AY, Fedorova OV, Maslova MN, Roukoyatkina NI, Ukhanova MV, Zhabko EP. Endogenous plasma Na, K-ATPase inhibitory activity and digoxin like immunoreactivity after acute myocardial infarction. Cardiovasc Res 25: 371-377, 1991.
15. + pump inhibitor in relation to haemodynamic data in cardiopathic patients. Clin Sci 81: 23-29, 1991.
16. Liu ZQ, Ma AQ, Zhang L, Yang DY. Intracellular electrolyte changes and levels of endogenous digoxin-like substance within the plasma in patients with congestive heart failure. Int J Cardiol 27: 147-153, 1990.
17. +]-dependent ATPase from cardiac tissue. Biochem Biophys Acuta 151: 655-663, 1968.
18. Shahi M, Thom S, Poulter N, et al. Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function. Lancet 336: 458-461, 1990 (see comments).
19. Tarazi RC. Regression of left ventricular hypertrophy by medical treatment: Present status and possible implications; in: The Heart and Hypertension, Masserli, FH, Ed., Yorke Medical Books, New York, 1987: 287-298.